Cancer Drugs

Key Takeaways: Global sales of BeiGene’s anti-tumor drug zanubrutinib more than doubled to $308 million (2.22 billion yuan) in the quarter BeiGene was slapped with a patent lawsuit by U.S. rival AbbVie in June, and suffered another blow to its global ambitions in July when Novartis pulled...

India Moves Towards Medical Independence: Cannabis Research Project Targets Cancer and Epilepsy The Cannabis Research Project by the Council of Scientific and Industrial Research - Indian Institute of Integrative Medicine (CSIR-IIIM) in Jammu, the most populous district in the Indian...

The FDA has approved Aadi Bioscience Inc's (NASDAQ: AADI) Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for perivascular epithelioid cell tumor (PEComa). The approval marks the first and only therapy for adult patients for locally advanced...

Epizyme Inc (NASDAQ: EPZM) and HUTCHMED (China) Limited (NASDAQ: HCM) have collaborated to research, develop, manufacture, and commercialize Tazverik (tazemetostat) in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. Tazverik is a methyltransferase...

Shares of Juno Therapeutics Inc (NASDAQ: JUNO) soared higher by 50 percent Wednesday after reports surfaced that the company is being targeted by Celgene Corporation (NASDAQ: CELG) for an acquisition. Here's what some of Wall Street's top analysts are saying. Morgan Stanley: Deal Could...

Merck & Co., Inc. (NYSE: MRK) announced encouraging data Tuesday from a key study of patients with lung cancer. The combination of Merck's blockbuster drug Keytruda and two chemotherapy medicines helped patients live longer and played a role in stopping the disease from advancing...

Pfizer Inc. (NYSE: PFE)'s pipeline consists of multiple growth assets that may be misunderstood by Wall Street analyst and investors. The Analyst Piper Jaffray's Richard Purkiss maintains an Overweight rating on Pfizer's stock with an unchanged $54 price target. The Thesis Pfizer...

It’s taking time, but three days after Gilead Sciences, Inc. (NASDAQ: GILD) announced its acquisition of Kite Pharma Inc (NASDAQ: KITE), the Street seems to be deciding it’s a good thing. Gilead’s stock traded up a modest 2.5 percent and three analysts reiterated Hold ratings...

Oasmia Pharmaceutical AB - American Depositary Shares (NASDAQ: OASM) is one of only three Swedish companies listed in the United States. While well known in Sweden, Oasmia entered the U.S. market in 2015 and is making waves in the world of oncology with a new drug delivery system that aims to...

Bristol-Myers Squibb Co (NYSE: BMY) saw its shares crater from near $75 last week to nearly $60 per share after the company reported a major setback for its cancer-treating drug, Opdivo. Bristol-Myers said Opdivo failed to meet a primary endpoint in the treatment of lung cancer during the...

Shares of Medivation Inc (NASDAQ: MDVN) were trading lower by more than 6 percent heading into Tuesday's market open as the company's drug pricing have come under scrutiny by the U.S. Congress. According to ABC News, a group of U.S. lawmakers initiated a campaign to potentially lower the price of...